Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Pulmonary Fibrosis

• The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects.
• Safety, Tolerability and Pharmacokinetic Study of SC1011 in Healthy Subjects
• Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
• SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
• A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis
• Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
• A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
• Open-Label Dose-Escalation Treatment Study of Patients With IPF
• Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis
• Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
• A Study to Investigate Leramistat in Patients With IPF
• Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
• Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
• A Study of PMG1015 Injection in Idiopathic Pulmonary Fibrosis Subjects
• Efficacy of Bailing Capsule on Pulmonary Fibrosis After COVID-19
• Clinical Study of Allogeneic Adipovarian Active Protein in the Treatment of Severe Idiopathic Pulmonary Fibrosis
• 99mTc-HFAPI SPECT/CT in Pulmonary Fibrosis
• Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis
• A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
• A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy Subjects
• Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis
• Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
• Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
• Treatment of Idiopathic Pulmonary Fibrosis(IPF) by REGEND001
• Study to Determine the Efficacy&Safety of ARV-1801/ACG-701 for the Treatment of Cystic Fibrosis Pulmonary Exacerbations
• Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)
• Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF) or Non-IPF Progressive Pulmonary Fibrosis
• Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
• Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
• Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis
• Atezolizumab for Idiopathic Pulmonary Fibrosis
• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF
• To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF
• To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
• Phase I Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
• Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers
• First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects
• A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis
• Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
• Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis
• Safety and Effectiveness of EV-Pure + WJ-Pure Treatment on Pulmonary Fibrosis Secondary to Covid-19
• To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers
• RESPIRARE Phase 2 Study of Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• FAPI PET for Lung Fibrosis
• A First-in-human Study of the Safety, Tolerability, and PK of XFB-19 in Healthy Adult Volunteers
• A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis
• A Study to Evaluate the Safety and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis
• LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
• Efficacy of Intensive Cholecalciferol Monitoring and Supplementation on Serum vitD Levels in Pediatric Patients With CF
• Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
• Xenon MRI and Progressive ILD
• Phase 2 Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With IPF
• Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
• A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects
• Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants
• CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis
• Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT
• Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）
• Phase ll Study of HEC585 in Patients With IPF
• Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF).
• A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
• A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015
• Efficacy of Steroid Pulse Therapy in Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF) Admitted in ER
• A Trial of SHR - 1906 in Healthy Subjects
• Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital
• A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
• Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole
• Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
• A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers
• Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19.
• Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
• To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers
• To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers
• A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
• Colchicine and Post-COVID-19 Pulmonary Fibrosis
• To Evaluate Food Effect on the PK and Safety After Oral DWN12088 Administration in Healthy Adult Volunteers
• A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects
• Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
• 129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study
• Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
• The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis
• The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
• Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19
• Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis
• A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
• TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis
• High-flow Oxygen Therapy During Exercise in Idiopathic Pulmonary Fibrosis
• A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
• Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis
• Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis
• Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF
• Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients
• Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects
• Morphine for Dyspnea in Pulmonary Fibrosis
• BIO 300 Oral Suspension in Discharged COVID-19 Patients
• Examination of Pirfenidone (Esbriet®) Therapy in Coal Workers' Pneumoconiosis With Pulmonary Fibrosis
• Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough
• Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
• A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
• Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis
• Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis
• Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
• Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19
• Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
• Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough
• Jaktinib Dihydrochloride Monohydrate in Idiopathic Pulmonary Fibrosis
• A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
• Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial
• Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu
• Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF
• Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects
• Jin-shui Huan-xian Granule in the Treatment of IPF
• Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/
• Genentech Xenon MRI Idiopathic Pulmonary Fibrosis
• A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough
• A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants
• Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary Fibrosis
• A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis
• Management of Progressive Disease in Idiopathic Pulmonary Fibrosis
• Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.
• GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
• A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects
• A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
• Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis
• A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
• Inhaled NAC in Treatment of IPF
• Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
• To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers
• Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults
• A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
• An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
• Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects
• JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF
• Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
• The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects
• Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
• This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.
• Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies
• A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
• Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis
• Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
• Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2)
• Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).
• Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT
• A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
• The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects
• Prednisone in Cystic Fibrosis Pulmonary Exacerbations
• Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging
• Nebulized Fentanyl in Patients With Mild to Moderate Interstitial Lung Disease and Chronic Dyspnea
• Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest
• Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension
• The Coagulation Cascade in Idiopathic Pulmonary Fibrosis
• Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial
• A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
• Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
• A Clinical Evaluation of Baofeikang Granule in Combined Pulmonary Fibrosis and Emphysema Treatment
• Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment
• Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment
• CleanUP IPF for the Pulmonary Trials Cooperative
• Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders
• Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
• Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
• A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)
• Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
• A Phase 2 Study of the Activity and Safety of KD025 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
• Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis
• A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
• An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
• Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
• Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone)
• First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients
• All-Case Surveillance of Ofev in Patients With IPF in Japan
• A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination
• Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
• Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)
• Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease
• Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF
• A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• 68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis
• Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis
• Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
• A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
• Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment
• 68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis
• Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis
• A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
• Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
• Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients
• Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects
• Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
• Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis
• 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF
• RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
• Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis
• Azithromycin in Idiopathic Pulmonary Fibrosis
• Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)
• A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
• Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone
• Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
• Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
• Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF)
• Nandrolone Decanoate in the Treatment of Telomeropathies
• Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis
• Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
• Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
• Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis
• Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab
• Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation
• Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
• A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
• Cromolyn Detection of Silent Aspiration
• Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole
• Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)
• Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
• Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)
• A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• Preventive Inhalation of Hypertonic Saline in Infants With Cystic Fibrosis
• Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease
• To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
• A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
• Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)
• Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)
• IPF Drug Deposition Study
• Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis
• Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)
• Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients
• STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
• Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis
• Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
• Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
• Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
• Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.
• Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
• Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis
• A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
• Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
• Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)
• Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patients
• Safety and PK Study of BIBF 1120 in Japanese Patients With IPF
• Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis
• Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis
• AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis
• Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease
• Effects of Mycophenolate Mofetil in Cystic Fibrosis Lung Transplant Patients
• Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study
• Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients
• Losartan in Treating Pulmonary Fibrosis in Patients With Stage I, II, or III Non-Small Cell Lung Cancer
• Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis
• ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
• A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
• (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
• Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
• Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
• Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis
• Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
• Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)
• Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study
• Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
• Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
• Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
• Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide
• QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis
• A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis
• SD, IL-13 Production Rate in IPF
• Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis
• Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis
• Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis
• Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
• Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide
• Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients
• Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis
• Study of Denufosol Inhalation Solution in Patients With Mild to Moderate Cystic Fibrosis Lung Disease
• BUILD 3: Bosentan Use in Interstitial Lung Disease
• Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis
• Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease
• Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension
• Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
• Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
• Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis
• Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study
• Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis
• Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
• Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study
• A Study in Pediatric Patients With Cystic Fibrosis Lung Disease
• Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis
• Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease
• Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
• An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF
• The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)
• Safety and Tolerability Study of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis
• Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis
• Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma
• Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis
• Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease
• An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone
• A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• Scleroderma Lung Disease
• Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
• Diffuse Fibrotic Lung Disease